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ABSTRACT
Introduction: Meticillin-resistant staphylococcus
aureus (MRSA) is an important cause of
antimicrobial-resistant infections worldwide.
Its prevalence remains high in the Greek
hospital setting. Complicated skin and soft
tissue infections (cSSTIs) due to MRSA are
associated with prolonged hospitalization,
additional healthcare costs and significant
morbidity. The purpose of this study was to
conduct a cost analysis and a budget impact
analysis relative to different management
scenarios for MRSA-cSSTIs from a hospital
perspective.
Methods: Equal efficacy was assumed for the
pharmacotherapies under evaluation and
resource use was elicited via an expert panel of
seven local infectious disease specialists. The
model was based on a previously published
economic model that was adapted for the Greek
hospital setting and included a decision tree for
the management of hospitalized patients with
MRSA-cSSTIs, which simulated costs and
outcomes for the duration of hospitalization
according to the therapeutic scenario. Inpatient
costs consisted of hospitalization, diagnostic/
laboratory testing, physician visits and
antibiotic treatment.
Results: Current economic impact of MRSA-
cSSTIs for the inpatient setting in Greek
hospitals was estimated at €29,196,218. Total
per patient cost according to first-line agent was
€2,457, €2,762, €2,850, €3,494 and €3,094 and
mean length of stay was 9.2, 12.5, 10.3, 13.0
and 14.0 days for linezolid, vancomycin,
daptomycin, tigecycline, and teicoplanin,
respectively. An estimated 10,287 MRSA-cSSTI
patients are treated annually in Greek hospitals.
Thus, increasing the use of linezolid by 11%
over a 3-year period (current use 19%; 3 year
projection 30%), for the management of
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MRSA-cSSTIs, could result in 3-year savings of
€896,065.
Conclusion: Management of MRSA-cSSTI
requires intensive resource use; overall
healthcare costs differ according to the chosen
first-line treatment. In light of considerable
budget constraints, development of hospital
strategies which facilitate early discharge, such
as the introduction of clinical criteria and
guidelines for switching from intravenous to
oral MRSA-cSSTI therapy, could result in
substantial savings for the Greek hospital
budget.
Keywords: Antibacterial agents; Complicated
skin and soft tissue infection; Cost analysis;




Complicated skin and soft tissue infections
(cSSTIs) are among the most common
infections treated in the hospital setting [1, 2].
They represent the more extreme end of the
clinical spectrum of SSTIs [3] as they typically
involve deep soft tissue and occur in patients
with underlying disease, often requiring
intravenous (IV) antibiotic therapy and/or
surgical intervention [2]. As a result, their
treatment incurs high healthcare costs. cSSTIs
frequently complicate clinically significant
medical conditions such as peripheral arterial
disease, diabetes mellitus or renal insufficiency
and can also cause complications in
immunocompromised hosts [4].
Gram-positive pathogens are the
predominant cause of cSSTIs. Staphylococcus
aureus (S. aureus) was found to be the most
frequently occurring pathogen among
hospitalized SSTI patients on a global scale in
the SENTRY Antimicrobial Surveillance Program
[5], and in a large observational study with 1995
cSSTIs patients hospitalized in Europe [1].
Antibiotic resistance in isolates from SSTIs has
increased significantly over time [6–10], but the
emergence of meticillin-resistant S. aureus
(MRSA) is recognized as the greatest resistance
concern [5], as it complicates the treatment of
cSSTIs, limits therapeutic options and impacts
treatment outcomes.
Systemic infections with MRSA are associated
with a higher mortality rate, a longer length of
stay (LOS) in hospital, and greater healthcare
costs than non-MRSA infections [11].
In Greece, where antimicrobial drug
resistance rates remain high [12], MRSA
prevalence reaches 40%, which is among the
highest in Europe [13] and comparable to
figures reported for the USA [14]. The increase
in MRSA, in part, reflects the changing
epidemiology of soft tissue infections as a
consequence of the recent dramatic increase in
the incidence of community acquired MRSA
(CA-MRSA), the pathogen most commonly
isolated from SSTIs in many locations in the
US [15]. CA-MRSA strains are distinct from
hospital-acquired strains, cause mainly skin
and soft tissue infections (ranging in severity
from furuncles to necrotizing fasciitis), and are
associated with the production of virulence
factors like the Panton Valentine Leukocidin
(PVL) toxin, which may further complicate
treatment [16]. In Europe, the prevalence of
infections due to CA-MRSA appear to vary
across the continent, with Greece reporting
one of the highest rates (30%) of S. aureus
infection in outpatients compared to 6–18% in
other Western European countries [16, 17].
Successful management of cSSTI involves
prompt recognition, timely surgical
debridement or drainage, resuscitation if
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required and appropriate antibiotic therapy [3].
Treatment for MRSA-related cSSTIs may include
either IV or per os (PO) pharmaceutical
treatment for 7–14 days and in most cases
hospitalization is required. Vancomycin
(VANCO) has historically been the standard of
care for MRSA infections, but adverse effects,
the need for IV access and growing resistance,
tend to limit its use [7]. Newer antimicrobials
such as daptomycin (DAPTO), linezolid (LINE)
and telavancin have shown comparable efficacy
to VANCO and are recommended in
international guidelines [18].
Use of proper antimicrobial treatment is an
illustrative example of the tradeoffs between
increased pharmaceutical spending and
decreased resource use costs. Given the
scarcity of economic and human healthcare
resources and the fact that the cost of available
antimicrobial treatments varies, the purpose of
the present study was to identify healthcare
resource use and cSSTI total inpatient costs,
along with other associated costs for different
antibiotic treatments in the Greek hospital
setting. A secondary objective was to perform




A previously published economic model [19]
was adapted for the Greek hospital setting, to
examine the healthcare resource use and
associated economic impact of different
management approaches for MRSA-cSSTIs. The
model was developed using Microsoft Excel and
Visual Basic, and was based on a decision tree
for the management of hospitalized patients
with MRSA-cSSTIs (Fig. 1), which simulated
costs and outcomes for the duration of
hospitalization according to different
therapeutic scenarios.
The time horizon for the decision tree was a
maximum of 14 days including inpatient
empirical and first-line treatment where all
patients remained hospitalized.
The most common first-line treatment
pathways in the management of MRSA-cSSTIs
were elicited from a panel of seven local experts
(infectious disease specialists), i.e., DAPTO,
LINE, teicoplanin (TEICO), tigecycline (TIGE),
and VANCO. Cotrimoxazole or tetracyclines
were not considered as, according to the
expert panel, these are most commonly used
for outpatients with mild SSTIs and are not
preferred in the management of hospitalized
patients with MRSA confirmed cSSTIs.
Efficacy rates for LINE and VANCO were
assumed to be equal in terms of clinical success
for the length of treatment (89.8%)—weighted
average between LINE clinical success rate (219
out of 239 treated cases) and VANCO clinical
success rate (193 out of 220 treated cases), as
reported by the non-inferiority study of Itani
et al. [20]. For the purpose of the analysis and
for simplicity reasons, DAPTO, TIGE and TEICO
were also assumed to present equal efficacy
rates. Regardless of efficacy assumptions, the
adverse event failure rate was calculated as (1-
success rate) 9 0.33, assuming 1/3 of treatment
failures are due to adverse events and 2/3 are
due to lack of efficacy [11]. Patients not cured
after receiving first-line antibiotic treatment or
who presented with adverse events were
assumed to be cured after receiving second-
line therapy. The set of patients who
discontinued or failed therapy required
additional hospitalization days as per the
input of the expert panel. As this study was
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conducted from a hospital perspective,
treatment continuation with second-line
agents in the outpatient setting was not
incorporated into the analysis.
Model Input Data
Treatment pathways and associated resource
use relevant to the local setting were obtained
from an expert panel, made up of seven
infectious disease specialists. To be included as
a member of the expert panel, each participant
was required to have long-term, recognized
professional experience in treating patients
with MRSA-cSSTIs. The panel was varied in
terms of level and setting of healthcare
provision, i.e., university clinics, NHS hospitals
and community clinics, as well as geographic
distribution across the Greek mainland.
Data were gathered using a series of closed
type questions pertaining to the current
management of a ‘‘typical’’ MRSA-cSSTI
patient treated in Greece. Resources included
hospitalization, hospital procedures, medical
visits, laboratory/diagnostic tests and
medication associated with MRSA-cSSTIs and
its complications. The mean values from all
expert responses gathered were used in the
study. In view of the lack of relevant data from
Greek hospitals, the panel of experts provided
information on estimated antibacterial use.
The expert panel also provided the
information on additional healthcare resource
requirements, collectively indicating that drug
failures and drug discontinuations due to
adverse events resulted in an additional seven
and five hospital days, respectively. Moreover,
an average per patient-per day hospitalization
cost for MRSA-cSSTIs was estimated based on
cSSTI diagnosis and diagnosis-related group
(DRG) mapping. This was deemed appropriate
as several DRG codes were identified by the
group of experts as being cSSTI relevant.
Continuation of first-line treatment in the
outpatient setting was not taken into
consideration due to the fact that the study
was conducted from a hospital perspective
only.
Fig. 1 General model outline for the ﬁrst-line management of hospitalized MRSA-cSSTI patients. cSSTI complicated skin
and soft tissue infections, MRSA meticillin-resistant Staphylococcus aureus
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The resource usage pattern for different
treatments (as elicited by the expert panel) is
reported in Table 1. Unit costs for antibiotic
agents and inpatient stays are reported in Table 2.
Model Outcomes
Inpatient costs consisted of hospitalization,
diagnostic/laboratory testing, physician visits
Table 2 Unit cost of inputs
Resource Input cost Source/assumption
Inpatient cost per day €189.20 Mean DRG cost for cSSTI,
weighted according to expert panel,
based on diagnosis [21]
Vancomycin IV 1 g (empiric—35%, ﬁrst line) €8.92 Cheapest generic selected [22]
Other IV empiric (daptomycin—26%, Linezolid—14%,
teicoplanin—9%, Tigecycline—12%, clindamycin—4%)
€33.89 Average weighted daily cost according to
usage % in the Greek hospital setting
Daptomycin IV 500 mg €87.50 [22]
Linezolid IV 600 mg €37.17 [22]
Linezolid PO tab 600 mg €32.80 [22]
Tigecycline IV 50 mg €37.10 [22]
Teicoplanin IV 400 mg €18.41 [22]
DRG diagnosis-related group, IV intravenous, PO per os (orally)
Table 1 First-line treatment resource use according to expert panel
Resource usagea Mean values reported by the expert panel
DAPTO LINE TEICO TIGE VANCO
No. of days of treatmentb 9.8 9.2 11.5 11.7 11.8
No. of days in hospitalc 10.3 9.2 14.0 13.0 12.5
No of days IV 9.8 6.7 12 11.7 11.8
Average daily dose (mg)d 458 1,200 500 133 2,000
IV doses per day 1.0 2.0 1.0 2.0 2.0
No. of days oral 0.0 2.5 0.0 0.0 0.0
Oral doses per day 0.0 2.0 0.0 0.0 0.0
Additional no. of days in hospital due to AE 5 5 5 5 5
Additional no. of days in hospital due to treatment failure 7 7 7 7 7
AE adverse events, DAPTO daptomycin, IV intravenous, LINE linezolid, TEICO teicoplanin, TIGE tigecycline, VANCO
vancomycin
a Values are calculated as means of expert panel feedback
b Excluding the treatment time prior to cultivation results
c Time from hospital admission to discharge
d Estimated for a ‘typical’ 75 kg patient
Infect Dis Ther (2014) 3:257–268 261
and antibiotic medication. Cost calculations
were based on the corresponding tariffs of all
services as reported in the official price lists of
the National Health System. Hospitalization
costs were based upon the current DRG system
[21]. Prices for medication were obtained from
the Official Price Bulletin [22]. All costs are
reported in Euros for the year 2013. The budget
impact analysis employed increasing market
share for the most cost-saving antibacterial
agent over a 3-year period, over the remaining
most commonly used antibacterial agents,
whose usage was decreased proportionally.
Finally, drug price erosion was not taken into
account.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Resource Use Pattern
According to the expert panel, MRSA-cSSTI
patients in Greece are 56.6% males and most
of them are over 60 years of age (57.1%).
Patients receive empirical treatment for
2.57 days on average, until a culture-based
antibiotic was selected. The panel also
concluded that side effects leading to
treatment discontinuation resulting from (any)
pharmaceutical treatment were reported for
25.7% of cSSTI-treated patients in the
inpatient setting (adverse events failure rate).
The average additional LOS due to
complications related to pharmaceutical
treatment was reported at 4.8 days. The
weighted mean DRG reimbursement cost per
hospitalization day for the inpatient
management of MRSA-cSSTI infections was
found to be 189.20 Euros. The proportion of
population matching each DRG-cSSTI code was
used as weights to calculate mean cost per
hospitalization day for the total cSSTI
population. The total annual inpatient cost
associated with cSSTIs currently in Greece was
estimated at €29,196,218.
According to Table 3, the total per patient
cost according to first-line agent was €2,457,
€2,762, €2,850, €3,094 and €3,494 for LINE,
VANCO, DAPTO, TEICO, and TIGE,
respectively. LINE as first-line treatment yields
the lowest total inpatient cost per patient
(€2,457) calculated per treatment cycle. This is
mostly attributed to the relatively low
hospitalization cost per patient (€1,889).
The current use of the most common
antibacterial agents in the management of
cSSTIs, as identified by the expert panel, along
with an estimated 3-year gradual increase of the
cost-saving antibacterial is presented in Table 4.
Table 5 summarizes the economic impact
resulting by gradually increasing LINE use for
the treatment of MRSA-cSSTIs from 19%
(current baseline case scenario) to 23% (year
1), to 27% (year 2) and up to 30% (year 3).
Previously conducted studies estimate that
10,287 MRSA-cSSTI patients are treated
annually in Greek hospitals [23, 24]. Inputting
these figures into the current study model
results in potential savings of €193,291 (year
1), €354,798 (year 2) and €347,977 (year 3)
compared to the current baseline case scenario,
thus a potential saving of €896,065 could be
made after 3 years.
Sensitivity Analysis
A series of one-way sensitivity analyses was
performed to test the robustness of outcomes
262 Infect Dis Ther (2014) 3:257–268
and the impact of individual variables on the
results. Table 6 [25, 26] summarizes the results.
Parameters with the most significant influence
on the results were LINE usage (expanded use
led to increased savings), LOS of treatment, and
efficacy (success rate) for comparators. Unit
prices for LINE and healthcare resources had a
lesser impact.














LINE 2,457 568 1,889 58 90
VANCO 2,762 249 2,513 58 90
DAPTO 2,850 753 2,097 58 90
TEICO 3,094 300 2,796 58 90
TIGE 3,494 886 2,607 58 90
AE adverse events, DAPTO daptomycin, LINE linezolid, TEICO teicoplanin, TIGE tigecycline, VANCO vancomycin
a Total mean cost per ‘‘typical’’ patient includes medical costs and antibiotic acquisition cost. Medical costs breakdown into
cost per day of hospitalization, treatment failure and adverse event costs
Table 4 Current and proposed antibacterial usage estimates
DAPTO LINE TEICO TIGE VANCO
Current cSSTIs usage estimate (%)a 26 19 9 11 35
Proposed usage estimate—year 1 (%) 23 23 10 10 34
Proposed usage estimate—year 2 (%) 19 27 10 10 34
Proposed usage estimate—year 3 (%) 18 30 11 11 30
cSSTI complicated skin and soft tissue infection, DAPTO daptomycin, LINE linezolid, TEICO teicoplanin, TIGE
tigecycline, VANCO vancomycin
a According to expert panel. Teicoplanin and tigecycline estimates considered stable. Any variations are due to rounding up
in order to result with assumed 100% share with the ﬁve treatment options
Table 5 Budget impact analysis of the gradual increase of LINE usage in the treatment of meticillin-resistant S. aureus
complicated skin and soft tissue infections
Current cost Cost after 1 year Cost after 2 years Cost after 3 years
Inpatient pharmaceuticals €5,305,213 €5,220,891 €5,145,002 €5,262,737
Difference -€84,322 -€160,211 -€42,476
Inpatient medical €23,891,005 €23,782,036 €23,696,418 €23,585,504
Difference -€108,968 -€194,586 -€305,501
Total budget impact €29,196,218 €29,002,927 €28,841,420 €28,848,241
Difference -€193,291 -€354,798 -€347,977
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DISCUSSION
Treatment of cSSTIs due to MRSA has significant
cost implications within the hospital setting, as
a result of additional LOS and extensive use of
appropriate healthcare resources. This study
aimed to (a) map the costs associated with
inpatient treatment of cSSTIs due to MRSA in
Greece, and (b) to analyze costs associated with
different antibacterial therapies and the
potential budget impact of increasing the
usage of the lowest cost agent.
For the baseline case scenario (depicting the
current treatment scenario in Greece), LINE
was shown to be the most cost-saving first-line
antimicrobial agent compared to other
treatment options. By extending the scope of
its current use (from 19% of patients to a
hypothetical 30%), the total (aggregate) budget
impact was €896,065 over a 3-year period.
Although LINE drug acquisition cost
approximates the average cost of the
remaining available treatments for cSSTI, its
use may result in significantly reduced medical
costs, namely hospitalization costs, compared
to other selected antibiotic treatments. Using
LOS data from a large phase IV study [20] for
the treatment of documented MRSA-cSSTIs,
LINE’s budget impact savings were further
increased to €1,893,600 for the 3-year period
Table 6 Budget impact results of the univariate sensitivity analyses
Change from baseline value Total 3-year budget impact for
increased use of LINE (€000s)
Baseline case scenarioa -896.1
5% change in LINE use (rise to 24%) -398.5
15% change in LINE use (rise to 34%) -1,976.4
Increase of LINE proportionally to all comparators -1,465.3
Equal LOS assumed for all comparators (14 days) 198.6
Differentiated LOS as reported by Itani et al. [20]b VANCO (mean 8.9 days) -359.8c
LINE (mean 7.6 days) -1,893.6
Differentiated efﬁcacy (success rate of treatment)
as reported by Itani et al. [20]b
VANCO (88%) -947.1
LINE (92%)
10% increase in the price of LINE -777.8
10% decrease in the price of LINE -1,006.1
10% increase in all medical costs -956.9
10% decrease in all medical costs -835.2
Alternative in-hospital per diem cost, as reported by WHO (309.65€), adjusted for
inﬂation [25, 26]d
-1,284.1
DAPTO daptomycin, LINE linezolid, LOS length of stay, TEICO teicoplanin, TIGE tigecycline, VANCO vancomycin,
WHO World Health Association
a LINE use for the treatment of MRSA-cSSTIs increased from 19% (current use) to 30% of cases during a 3-year period
b Not assumed equal as in the baseline case scenario
c Based on the same usage assumptions as in baseline case scenario
d Converted from international dollars
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(Table 6). Clinical data demonstrates 100%
bioavailability [27] of the oral LINE
formulation, thus allowing continuation of
therapy in both the inpatient and outpatient
setting when clinically appropriate and
without dosage adjustment.
In addition to reducing LOS and healthcare
costs, the Infectious Diseases Society of America
and the Society for Healthcare Epidemiology of
America Guidelines suggest that conversion
from parenteral to oral therapy using
antimicrobials with excellent bioavailability,
when the patient’s condition allows, can
reduce complications that may arise as a result
of IV access. An antimicrobial management
program which outlines clinical criteria and
guidelines for oral switch could play an
important role in safeguarding the balance
between incremental antimicrobial acquisition
costs and the development of resistance at an
institutional level [28].
Hospitalization has been recognized within
international literature as the main cost driver
in the treatment of MRSA infections,
comprising up to 81% of total treatment costs
and making early discharge a reasonable target
for savings [29, 30]. A recent retrospective chart
review in 12 European countries [26] has shown
that by applying early discharge criteria in
MRSA-cSSTIs more than one-third of
hospitalized patients in usual clinical practice
could be discharged from the hospital (37.9%
overall and 41.1% for Greece with a mean ± SD
potential LOS reduction of 6.2 ± 8.2 and
7.5 ± 10.6 days, respectively).
A treatment strategy that would focus on
early discharge followed by outpatient
parenteral treatment (OPAT) use or use of
orally available antimicrobials could be of
benefit. However, OPAT treatment is rather
costly and is not commonly used in the Greek
NHS setting [31].
As with every study of this kind, the
outcomes must be interpreted in light of a
number of limitations. First of all, the study
design assumes equal effectiveness among the
different treatment schedules. This probably
leads to conservative estimations, considering
that data from a recent systematic meta-analysis
of 14 studies of six antibiotics (n = 1,840)
suggested differences in efficacy of different
MRSA-cSSTI pharmaceutical treatments [32],
mostly in favor of LINE. The assumption that
all patients are cured after receiving second-line
treatment and that no patients died represents a
simplification of reality. The majority of studies
in cSSTIs do report high clinical success and
very low mortality rates [15] which are similar
for patients treated with LINE or VANCO [20],
however, second-line efficacy data are lacking.
All model assumptions were based on a
previously published model [19] and were
considered reasonable by the panel of experts.
Moreover, the option of outpatient oral and IV
treatment continuation was not taken into
consideration as this falls beyond the scope of
the study (hospital setting). However, this could
have a substantial impact on total cost of
treatment [33], especially from an overall
healthcare system perspective. Recent evidence
shows that the administration of antibacterial
treatment administered on an outpatient basis
can reduce per patient costs up to 30% [19].
Another limitation to be considered is the lack
of Greek-specific pharmaceutical use and MRSA-
cSSTI prevalence data. The use of an expert panel
approach implies a level of uncertainty with
respect to the data acquisition process [34].
Furthermore, results may not be fully
transferable to other treatment settings, as
significant variation exists in clinical practice
[31]. The actual magnitude of this uncertainty is
very difficult to quantify. However, the
multidisciplinary make-up of the team of
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experts and the consistency of estimations
produced by expert panels in Greece, as
reported by previous research [35] enhance the
robustness of results. Moreover, recently
published data on patients’ age and sex, mean
LOS and IV use in Greece from a retrospective
study in 12 European countries [31] are
consistent with the results of the expert panel.
In actual terms, the economic benefits of
LINE are heavily based on its ability to reduce
LOS and associated hospital costs. This was
evident in the case where equal LOS was
hypothesized for all comparators, which
resulted in VANCO being the least costly
choice. Newer agents have been shown to
reduce LOS and thus may offset (partially or
fully) the costs of medication.
Finally, the use of the recently introduced
DRGs costing system leads to an
underestimation of the relevant costs. This is
because the current DRG price lists in Greece do
not include staff costs. This is likely to result in
an underestimation of the actual cost of treating
cSSTIs due to MRSA, especially within the
hospital setting. It has to be noted that the
average hospitalization cost per day for cSSTIs
based on the DRG reimbursement system was
found to be approximately half the respective
cost compared to recently published literature
in the Greek setting [31] and the World Health
Organization for inpatient cost per day (309.65
adjusted for inflation in 2012) [25, 26].
Furthermore, as with most pharmacoeconomic
studies, drug acquisition costs used in the cost
calculations lack consideration for price
variation over time.
Notwithstanding its limitations, this study is
an illustrative example of the importance of
global hospital budget, where higher drug
acquisition costs would be offset by the
marked reduction in hospital and fixed costs
due to early discharge.
CONCLUSION
According to current clinical practice, as
depicted by the panel of experts in the present
study, LINE is associated with the lowest total
costs in the management of the ‘‘typical’’ MRSA-
cSSTI patient. The lower costs for patients
treated with LINE can be attributed to a switch
to oral therapy and earlier hospital discharge.
International experience shows that early
discharge, when certain criteria are met, can
reduce healthcare costs without compromising
quality of care. In light of considerable hospital
budget constraints, the development of hospital
strategies to facilitate early discharge of
patients, for example by introducing clinical
criteria and guidelines for switching to oral
treatments for MRSA-cSSTIs, could result in
substantial savings for the Greek global
hospital budget.
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